Evidence map›Paper›PMID 40606602›Full record

SynthesisFrontiers in pharmacology2025

Efficacy and safety of shensong yangxin capsules for persistent atrial fibrillation: a Systematic Review and meta-analysis of randomized controlled trials.

Yifan Chen, Liuding Wang, Yuying Li, Runa A, Jiahui OuYang, Zhonghui Jiang, Zhuye Gao

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yifan Chen *Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Liuding Wang *Department of Neurology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Yuying LiCollege of Basic Medicine, Capital Medical University, Beijing, China.
Runa ADepartment of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Jiahui OuYangDepartment of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Zhonghui JiangDepartment of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Zhuye GaoDepartment of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Shensong Yangxin (SSYX), a standardized Chinese preparation, is widely utilized in arrhythmia treatment. This research sought to assess the clinical advantages of SSYX for persistent atrial fibrillation (PsAF). Methods: We searched seven databases and two registries to identify randomized controlled trials (RCTs) assessing SSYX as an adjunctive treatment for PsAF. We assessed methodological quality with the Cochrane Risk of Bias Tool 2.0, and conducted meta-analyses with RevMan 5.4. Results: The meta-analysis incorporated ten RCTs enrolling 1,713 patients with PsAF. SSYX combined with conventional treatments (CTs) significantly lowered the recurrence of AF compared to CTs alone (risk ratio [ Conclusion: SSYX showed potential in preventing AF recurrence in PsAF patients. Nevertheless, these preliminary findings require validation through more rigorously designed trials, given methodological limitations impacting evidence certainty. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251008974, identifier CRD420251008974.

Indexed as

meta-analysispersistent atrial fibrillationShensong Yangxin capsuleSystematic reviewtraditional Chinese medicine

Identifiers

PMID40606602
PMCPMC12213544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.